Obesity Surgery

, Volume 18, Issue 9, pp 1134–1143 | Cite as

The Bone-Adipose Axis in Obesity and Weight Loss

  • J. Gómez-Ambrosi
  • A. Rodríguez
  • V. Catalán
  • G. Frühbeck


Body fat and lean mass are correlated with bone mineral density, with obesity apparently exerting protection against osteoporosis. The pathophysiological relevance of adipose tissue in bone integrity resides in the participation of adipokines in bone remodeling through effects on deposition and resorption. On the other hand, the skeleton has recently emerged as an endocrine organ with effects on body weight control and glucose homeostasis through the actions of bone-derived factors such as osteocalcin and osteopontin. The cross-talk between adipose tissue and the skeleton constitutes a homeostatic feedback system with adipokines and molecules secreted by osteoblasts and osteoclasts representing the links of an active bone–adipose axis. Given the impact of bariatric surgery on absorption and the adipokine secretory pattern, to focus on the changes taking place following surgical-induced weight loss on this dynamic system merits detailed consideration.


Bone mass Obesity Adipose tissue Adipokines Osteokines 



The authors gratefully acknowledge the funding of their experimental work by grants from the Spanish Instituto de Salud Carlos III (FIS PI030381, FIS PI061458, and FIS PI06/90288) from the Ministerio de Sanidad y Consumo, as well as by grants 20/2005 and 3/2006 from the Department of Health of the Gobierno de Navarra, Spain and from the PIUNA Foundation. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Spain.


  1. 1.
    Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791–801.PubMedGoogle Scholar
  2. 2.
    Rosen CJ, Bouxsein ML. Mehanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006;2:35–43.PubMedGoogle Scholar
  3. 3.
    Frühbeck G. Hunting for new pieces to the complex puzzle of obesity. Proc Nutr Soc. 2006;65:329–47.PubMedGoogle Scholar
  4. 4.
    Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19:595–606.PubMedGoogle Scholar
  5. 5.
    Zhao LJ, Liu YJ, Liu PY, et al. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab. 2007;92:1640–6.PubMedGoogle Scholar
  6. 6.
    Galusca B, Zouch M, Germain N, et al. Constitutional thinness: unusual human phenotype of low bone quality. J Clin Endocrinol Metab. 2008;93:110–7.PubMedGoogle Scholar
  7. 7.
    Hla MM, Davis JW, Ross PD, et al. A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. Am J Clin Nutr. 1996;64:354–60.PubMedGoogle Scholar
  8. 8.
    Bélanger C, Luu-The V, Dupont P, et al. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res. 2002;34:737–45.PubMedGoogle Scholar
  9. 9.
    Anandacoomarasamy A, Caterson I, Sambrook P, et al. The impact of obesity on the musculoskeletal system. Int J Obes. 2008;32:211–22.Google Scholar
  10. 10.
    Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001;280:E827–47.PubMedGoogle Scholar
  11. 11.
    Gómez-Ambrosi J, Frühbeck G. Unlocking the molecular basis of obesity. Future Lipidol. 2007;2:577–81.Google Scholar
  12. 12.
    Oh KW, Lee WY, Rhee EJ, et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol. 2005;63:131–8.Google Scholar
  13. 13.
    Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab. 2007;92:2046–52.PubMedGoogle Scholar
  14. 14.
    Peng XD, Xie H, Zhao Q, et al. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta. 2008;387:31–5.PubMedGoogle Scholar
  15. 15.
    Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–69.PubMedGoogle Scholar
  16. 16.
    Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393:7–20.PubMedGoogle Scholar
  17. 17.
    Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92:73–8.PubMedGoogle Scholar
  18. 18.
    Burguera B, Hofbauer LC, Thomas T, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology. 2001;142:3546–53.PubMedGoogle Scholar
  19. 19.
    Hamrick MW, Della-Fera MA, Choi YH, et al. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res. 2005;20:994–1001.PubMedGoogle Scholar
  20. 20.
    Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197–207.PubMedGoogle Scholar
  21. 21.
    Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 2006;4:341–8.PubMedGoogle Scholar
  22. 22.
    Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305–17.PubMedGoogle Scholar
  23. 23.
    Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434:514–20.PubMedGoogle Scholar
  24. 24.
    Fu L, Patel MS, Bradley A, et al. The molecular clock mediates leptin-regulated bone formation. Cell. 2005;122:803–15.PubMedGoogle Scholar
  25. 25.
    Reid IR. Leptin deficiency-lessons in regional differences in the regulation of bone mass. Bone. 2004;34:369–71.PubMedGoogle Scholar
  26. 26.
    Hamrick MW, Ferrari SL. Leptin and the sympathetic connection of fat to bone. Osteoporos Int. 2008;19:905–12.PubMedGoogle Scholar
  27. 27.
    Gordeladze JO, Reseland JE. A unified model for the action of leptin on bone turnover. J Cell Biochem. 2003;88:706–12.PubMedGoogle Scholar
  28. 28.
    Pasco JA, Henry MJ, Kotowicz MA, et al. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab. 2001;86:1884–7.PubMedGoogle Scholar
  29. 29.
    Blain H, Vuillemin A, Guillemin F, et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2002;87:1030–5.PubMedGoogle Scholar
  30. 30.
    Thomas T, Burguera B, Melton LJ, 3rd et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone. 2001;29:114–20.PubMedGoogle Scholar
  31. 31.
    Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 2008;582:74–80.PubMedGoogle Scholar
  32. 32.
    Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35:842–9.PubMedGoogle Scholar
  33. 33.
    Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem. 2006;99:196–208.PubMedGoogle Scholar
  34. 34.
    Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21:1648–56.PubMedGoogle Scholar
  35. 35.
    Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331:520–6.PubMedGoogle Scholar
  36. 36.
    Yamaguchi N, Kukita T, Li YJ, et al. Adiponectin inhibits induction of TNF-α/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett. 2008;582:451–6.PubMedGoogle Scholar
  37. 37.
    Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309:99–109.PubMedGoogle Scholar
  38. 38.
    Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33:646–51.PubMedGoogle Scholar
  39. 39.
    Jürimäe J, Jürimäe T. Adiponectin is a predictor of bone mineral density in middle-aged premenopausal women. Osteoporos Int. 2007;18:1253–9.PubMedGoogle Scholar
  40. 40.
    Richards JB, Valdes AM, Burling K, et al. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92:1517–23.PubMedGoogle Scholar
  41. 41.
    Tamura T, Yoneda M, Yamane K, et al. Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. Metabolism. 2007;56:623–8.PubMedGoogle Scholar
  42. 42.
    Gómez-Ambrosi J, Frühbeck G. Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev. 2005;1:227–34.PubMedGoogle Scholar
  43. 43.
    Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006;99:824–34.PubMedGoogle Scholar
  44. 44.
    Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med. 2005;11:344–7.PubMedGoogle Scholar
  45. 45.
    Xie H, Tang SY, Luo XH, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 2007;80:201–10.PubMedGoogle Scholar
  46. 46.
    Rodríguez A, Catalán V, Gómez-Ambrosi J, et al. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des. 2007;13:2169–75.PubMedGoogle Scholar
  47. 47.
    Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75–9.PubMedGoogle Scholar
  48. 48.
    Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88–91.PubMedGoogle Scholar
  49. 49.
    Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone. 2005;37:601–6.PubMedGoogle Scholar
  50. 50.
    Papadopoulos NG, Georganas K, Skoutellas V, et al. Correlation of interleukin-6 serum levels with bone density in postmenopausal women. Clin Rheumatol. 1997;16:162–5.PubMedGoogle Scholar
  51. 51.
    Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001;86:2032–42.PubMedGoogle Scholar
  52. 52.
    Khosla S, Peterson JM, Egan K, et al. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab. 1994;79:707–11.PubMedGoogle Scholar
  53. 53.
    Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986;319:516–8.PubMedGoogle Scholar
  54. 54.
    Wennberg P, Nordstrom P, Lorentzon R, et al. TNF-α gene polymorphism and plasma TNF-α levels are related to lumbar spine bone area in healthy female Caucasian adolescents. Eur J Endocrinol. 2002;146:629–34.PubMedGoogle Scholar
  55. 55.
    Pfeilschifter J, Chenu C, Bird A, et al. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res. 1989;4:113–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000;191:275–86.PubMedGoogle Scholar
  57. 57.
    Catalán V, Gómez-Ambrosi J, Ramírez B, et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg. 2007;17:1464–74.PubMedGoogle Scholar
  58. 58.
    Martin TJ. A skeleton key to metabolism. Nat Med. 2007;13:1021–3.PubMedGoogle Scholar
  59. 59.
    Scatena M, Liaw L, Giachelli CM. Osteopontin. A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302–9.PubMedGoogle Scholar
  60. 60.
    Reinholt FP, Hultenby K, Oldberg A, et al. Osteopontin—a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 1990;87:4473–5.PubMedGoogle Scholar
  61. 61.
    Gómez-Ambrosi J, Catalán V, Ramírez B, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007;92:3719–27.PubMedGoogle Scholar
  62. 62.
    Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117:2877–88.PubMedGoogle Scholar
  63. 63.
    Kiefer FW, Zeyda M, Todoric J, et al. Osteopontin expression in human and murine obesity: extensive local upregulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008;149:1350–7.PubMedGoogle Scholar
  64. 64.
    Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996;17:333–68.PubMedGoogle Scholar
  65. 65.
    Ferron M, Hinoi E, Karsenty G, et al. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008;105:5266–70.PubMedGoogle Scholar
  66. 66.
    Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.PubMedGoogle Scholar
  67. 67.
    Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–5.PubMedGoogle Scholar
  68. 68.
    Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–8.PubMedGoogle Scholar
  69. 69.
    Holecki M, Zahorska-Markiewicz B, Janowska J, et al. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity. 2007;15:1925–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Gannagé-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008;158:353–9.PubMedGoogle Scholar
  71. 71.
    Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192–4.PubMedGoogle Scholar
  72. 72.
    Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631–7.PubMedGoogle Scholar
  73. 73.
    Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175–80.PubMedGoogle Scholar
  74. 74.
    An JJ, Han DH, Kim DM, et al. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J. 2007;48:765–72.PubMedGoogle Scholar
  75. 75.
    Skopkova M, Penesova A, Sell H, et al. Protein array reveals differentially expressed proteins in subcutaneous adipose tissue in obesity. Obesity. 2007;15:2396–406.PubMedCrossRefGoogle Scholar
  76. 76.
    Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001;107:1049–54.PubMedGoogle Scholar
  77. 77.
    Bradshaw AD, Graves DC, Motamed K, et al. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc Natl Acad Sci USA. 2003;100:6045–50.PubMedGoogle Scholar
  78. 78.
    Delany AM, Amling M, Priemel M, et al. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest. 2000;105:915–23.PubMedGoogle Scholar
  79. 79.
    Tartare-Deckert S, Chavey C, Monthouel MN, et al. The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity. J Biol Chem. 2001;276:22231–7.PubMedGoogle Scholar
  80. 80.
    Chavey C, Boucher J, Monthouel-Kartmann MN, et al. Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia. Obesity. 2006;14:1890–7.PubMedGoogle Scholar
  81. 81.
    Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med. 2006;166:2502–10.PubMedGoogle Scholar
  82. 82.
    Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151–84.PubMedGoogle Scholar
  83. 83.
    Pace DG, Blotner S, Guerciolini R. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr. 2001;131:1694–9.PubMedGoogle Scholar
  84. 84.
    Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord. 2001;25:1154–60.PubMedGoogle Scholar
  85. 85.
    Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246–51.PubMedGoogle Scholar
  86. 86.
    Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–94.PubMedGoogle Scholar
  87. 87.
    Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005;365:1363–4.PubMedGoogle Scholar
  88. 88.
    Tam J, Trembovler V, Di Marzo V, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 2008;22:285–94.PubMedGoogle Scholar
  89. 89.
    Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008;153:182–8.PubMedGoogle Scholar
  90. 90.
    Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–18.PubMedGoogle Scholar
  91. 91.
    Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother. 2007;41:2014–8.PubMedGoogle Scholar
  92. 92.
    Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30:1574–6.PubMedGoogle Scholar
  93. 93.
    Lin TH, Yang RS, Tang CH, et al. PPARγ inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone. 2007;41:562–74.PubMedGoogle Scholar
  94. 94.
    Wan Y, Chong LW, Evans RM. PPAR-γ regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496–503.PubMedGoogle Scholar
  95. 95.
    Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2005;353:595–603.PubMedGoogle Scholar
  96. 96.
    Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061–5.PubMedGoogle Scholar
  97. 97.
    Wucher H, Ciangura C, Poitou C, et al. Effects of weight loss on bone status after bariatric surgery: association between adipokines and bone markers. Obes Surg. 2008;18:58–65.PubMedGoogle Scholar
  98. 98.
    Kral JG, Näslund E. Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab. 2007;3:574–83.PubMedGoogle Scholar
  99. 99.
    Saber AA, Elgamal MH, McLeod MK. Bariatric surgery: the past, present, and future. Obes Surg. 2008;18:121–8.PubMedGoogle Scholar
  100. 100.
    Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg. 2003;13:383–8.PubMedGoogle Scholar
  101. 101.
    Olmos JM, Vazquez LA, Amado JA, et al. Mineral metabolism in obese patients following vertical banded gastroplasty. Obes Surg. 2008;18:197–203.PubMedGoogle Scholar
  102. 102.
    Strauss BJ, Marks SJ, Growcott JP, et al. Body composition changes following laparoscopic gastric banding for morbid obesity. Acta Diabetol. 2003;40 Suppl 1:S266–9.PubMedGoogle Scholar
  103. 103.
    von Mach MA, Stoeckli R, Bilz S, et al. Changes in bone mineral content after surgical treatment of morbid obesity. Metabolism. 2004;53:918–21.Google Scholar
  104. 104.
    Giusti V, Gasteyger C, Suter M, et al. Gastric banding induces negative bone remodelling in the absence of secondary hyperparathyroidism: potential role of serum C telopeptides for follow-up. Int J Obes. 2005;29:1429–35.Google Scholar
  105. 105.
    Goode LR, Brolin RE, Chowdhury HA, et al. Bone and gastric bypass surgery: effects of dietary calcium and vitamin D. Obes Res. 2004;12:40–7.PubMedGoogle Scholar
  106. 106.
    Ott MT, Fanti P, Malluche HH, et al. Biochemical evidence of metabolic bone disease in women following Roux-Y gastric bypass for morbid obesity. Obes Surg. 1992;2:341–8.PubMedGoogle Scholar
  107. 107.
    El-Kadre LJ, Rocha PRS, de Almeida Tinoco AC, et al. Calcium metabolism in pre- and postmenopausal morbidly obese women at baseline and after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2004;14:1062–6.PubMedGoogle Scholar
  108. 108.
    Riedt CS, Brolin RE, Sherrell RM, et al. True fractional calcium absorption is decreased after Roux-en-Y gastric bypass surgery. Obes Res. 2006;14:1940–8.Google Scholar
  109. 109.
    Schweitzer DH. Mineral metabolism and bone disease after bariatric surgery and ways to optimize bone health. Obes Surg. 2007;17:1510–6.PubMedGoogle Scholar
  110. 110.
    Compher CW, Badellino KO, Boullata JI. Vitamin D and the bariatric surgical patient: a review. Obes Surg. 2008;18:220–4.PubMedGoogle Scholar
  111. 111.
    Duran de Campos C, Dalcanale L, Pajecki D, et al. Calcium intake and metabolic bone disease after eight years of Roux-en-Y gastric bypass. Obes Surg. 2008;18:386–90.PubMedGoogle Scholar
  112. 112.
    Johnson JM, Maher JW, Samuel I, et al. Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone, and vitamin D. J Gastrointest Surg. 2005;9:1106–10.PubMedGoogle Scholar
  113. 113.
    Goldner WS, Stoner JA, Thompson J, et al. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: a comparison with non-obese controls. Obes Surg. 2008;18:145–50.PubMedGoogle Scholar
  114. 114.
    Newbury L, Dolan K, Hatzifotis M, et al. Calcium and vitamin D depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg. 2003;13:893–5.PubMedGoogle Scholar
  115. 115.
    Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg. 2004;8:48–55.PubMedGoogle Scholar
  116. 116.
    Moreiro J, Ruiz O, Perez G, et al. Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes Surg. 2007;17:348–54.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • J. Gómez-Ambrosi
    • 1
    • 2
  • A. Rodríguez
    • 1
    • 2
  • V. Catalán
    • 1
    • 2
  • G. Frühbeck
    • 1
    • 2
    • 3
  1. 1.Metabolic Research Laboratory, Clínica Universitaria de NavarraUniversity of NavarraPamplonaSpain
  2. 2.CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN)Instituto de Salud Carlos IIIPamplonaSpain
  3. 3.Department of Endocrinology, Clínica Universitaria de NavarraUniversity of NavarraPamplonaSpain

Personalised recommendations